Fluspirilene (Imap, Redeptin): Why This Weekly Depot Is Not in U.S. Pharmacies and What Telehealth Can Still Do

Last updated: August 25, 2026

Fluspirilene is a first-generation diphenylbutylpiperidine antipsychotic. Clinicians outside the United States still know it as Imap or Redeptin. It is given as a weekly intramuscular depot, not as a home tablet. U.S. retail pharmacies do not stock this medicine as a current option. This guide explains what fluspirilene is, what Cochrane actually found, and how telehealth can still help someone who needs an evaluation for psychosis, anxiety, or related symptoms.

This page is educational. It is not a diagnosis, a refill promise, or a claim that any plan will pay for a specific drug. Coverage varies by plan. Verify benefits before you book.

See conditions Klarity treats or start with online anxiety treatment if worry, restlessness, or tension is the main problem you want to discuss.

TL;DR

• DrugBank (DB04842) describes fluspirilene as a long-acting injectable antipsychotic used for schizophrenia. Brands include Imap and Redeptin. Codes: R 6218, McN-JR-6218. (DrugBank DB04842)
• Identifiers: CAS 1841-19-6; UNII C5QA4GLR9M; PubChem CID 3396; ATC N05AG01 (diphenylbutylpiperidine group, same family as pimozide). Formula C29H31F2N3O; average mass about 475.57. Janssen U.S. Patent 3,238,216 (March 1, 1966).
• Wikipedia and pharmacokinetic tables list Imap/Redeptin as a typical depot in aqueous microcrystalline suspension, often 2-12 mg once a week, Tmax 1-8 days, single-dose half-life about 7 days. Those figures describe historic clinic use abroad. They are not a U.S. prescription you can fill at a neighborhood pharmacy.
• Cochrane review CD001718 (Abhijnhan et al., 2007) included 12 randomized trials, most small and short. Reviewers found no clear advantage versus oral antipsychotics or other depots on relapse or global state. Extrapyramidal effects were less common versus some other depots in pooled data (RR 0.50). Trial-derived data still cannot tell a clinician whether to pick fluspirilene over another depot. (Cochrane CD001718)
• Do not import unlabeled ampoules or research chemical. DrugBank flags QTc-prolonging and CYP3A4-substrate categories. A weekly shot belongs in a clinic, not a video visit.
• Medicare behavioral telehealth in the home remains available on a permanent basis, with several other Medicare telehealth flexibilities extended through December 31, 2027 (HHS page last updated February 5, 2026). Klarity’s 2,000+ licensed providers can evaluate current symptoms and discuss medicines that U.S. pharmacies still stock. (HHS telehealth policy updates)

On this page

• What is fluspirilene?
• Imap, Redeptin, and the weekly depot
• How this diphenylbutylpiperidine is described
• What the Cochrane review found
• Safety, class risks, and what not to do
• What telehealth can still do
• How Klarity fits
• FAQ

What is fluspirilene?

Fluspirilene is a typical antipsychotic in the diphenylbutylpiperidine class, the same chemical family as pimozide (Orap). DrugBank’s one-line summary is direct: an antipsychotic used for schizophrenia, and in the background field a long-acting injectable for chronic schizophrenia. ATC code N05AG01 sits under N05AG, diphenylbutylpiperidine derivatives.

PubChem lists CID 3396. DrugBank lists formula C29H31F2N3O and average molecular weight 475.5727. IUPAC name: 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one. External IDs include R 6218 and McN-JR-6218. Janssen discovered the molecule; the 1966 U.S. patent is 3,238,216. A 1970 pharmacology paper and a 1970 clinical series still appear on the Wikipedia reference list (Arzneimittelforschung; Psychiatr Neurol Neurochir).

If you found “Imap” on a European clinic card, you are looking at fluspirilene. If you only searched “Redeptin,” you are still looking at the same weekly depot. Do not confuse it with pimozide tablets. Pimozide is a related structure that U.S. labels reserve for severe Tourette tics after other options fail. Fluspirilene is the injectable cousin that never became a U.S. retail product.

Imap, Redeptin, and the weekly depot

Unlike oil-based decanoate shots given every two to four weeks, fluspirilene is usually described as an aqueous microcrystalline suspension given once a week. Wikipedia’s long-acting injectable table lists brand names Imap and Redeptin, typical dose 2-12 mg every week, Tmax 1-8 days, and a single-dose half-life of about 7 days. DrugBank’s dosage-form table lists intramuscular suspensions at 2 mg/mL and 10 mg/mL, plus parenteral injections at 1.5 mg and 12 mg. Treat those strengths as historic commercial facts from markets that still, or once, stocked the product.

A U.S. clinician cannot fill Imap at a standard U.S. retail pharmacy. Do not copy a European weekly milligram onto leftover ampoules or an overseas order. A video visit cannot inject a depot.

How this diphenylbutylpiperidine is described

Typical antipsychotics in this family block dopamine D2 receptors. DrugBank also files fluspirilene under dopamine D2 antagonists, serotonin 5-HT2A antagonists, moderate-risk QTc-prolonging agents, and CYP3A4 substrates. That last point matters if someone still has an old overseas chart: many common antifungals, macrolides, and grapefruit-type CYP3A4 inhibitors sit on interaction lists for this class.

The weekly aqueous depot is the clinical personality of the drug. Families often search it after a move from Germany, the Netherlands, or another European system that used Imap for maintenance schizophrenia. The U.S. answer is substitution with an FDA-available oral or long-acting antipsychotic, not an Imap transfer.

Browse condition pages if you need a starting point for what a visit can cover.

What the Cochrane review found

Abhijnhan, Adams, David, and Ozbilen updated “Depot fluspirilene for schizophrenia” in 2007 (CD001718). They included 12 randomized trials, five of them new since the 1999 version. Most studies were small and short, which is a weak evidence base for a maintenance shot.

Headline findings from the Cochrane plain-language and abstract pages:

• One placebo comparison (n=60) did not show an important difference in global improvement (RR “no important improvement” 0.97, CI 0.9 to 1.1). Movement disorders appeared only in the fluspirilene group in that trial (RR 31.0, NNH 4).
• Versus other depots, short-term CGI “no important improvement” was not significantly different (n=90, 2 RCTs, RR 0.80). Relapse and early dropout were also not clearly different.
• Extrapyramidal adverse effects were less common with fluspirilene than with some comparator depots (n=164, 4 RCTs, RR 0.50, NNH 5).
• Versus oral antipsychotics, relapse and leaving the study early did not differ in a way reviewers trusted. Weekly versus every-other-week fluspirilene (n=34) was too small to interpret.
• No included study reported hospital use, patient satisfaction, or cost.

The authors’ conclusion is blunt: participant numbers were small, and the choice of whether to use fluspirilene cannot be informed by trial-derived data. That is the honest answer if a family member still has Imap on an old discharge list.

Safety, class risks, and what not to do

First-generation antipsychotics share a familiar risk set even when the brand is gone:

• Extrapyramidal reactions: tremor, rigidity, akathisia, dystonia.
• Tardive dyskinesia with long-term dopamine blockade.
• Neuroleptic malignant syndrome: fever, rigidity, autonomic instability. That is an emergency, not a telehealth follow-up.
• QTc prolongation risk (DrugBank category: moderate-risk QTc-prolonging agent).
• Higher death risk in older adults with dementia-related psychosis is a class boxed warning on U.S. antipsychotic labels. Fluspirilene is not a U.S.-approved option for that use.

Do not buy fluspirilene from a research catalog. Do not inject leftover European ampoules without a licensed clinician and a legal supply chain. If someone is in crisis now, call or text 988. Telehealth is the wrong channel for NMS, severe rigidity, or sudden collapse. Poison Control: 1-800-222-1222.

What telehealth can still do

Klarity does not prescribe fluspirilene. The molecule is not a U.S. telehealth medicine. A licensed clinician can still review symptoms, history, and current options that U.S. pharmacies actually stock. That may include education, a plan for in-person depot care if a different long-acting shot is appropriate, or follow-up for anxiety and mood symptoms that sit next to an old psychosis diagnosis.

HHS states that Medicare behavioral telehealth in the home remains available on a permanent basis, and that recent legislation extended many other Medicare telehealth flexibilities through December 31, 2027 (page last updated February 5, 2026).

New or worsening psychosis with danger to self or others, suspected NMS, or inability to stay safe at home needs emergency or in-person care. A weekly intramuscular depot cannot be started on a video visit.

How Klarity fits

Klarity’s network includes 2,000+ licensed U.S. providers. You can start with a condition overview, then book a visit if a clinician agrees telehealth is appropriate. We do not promise that any plan will cover a specific medicine or visit type. Coverage varies by plan. Verify benefits before you book.

See if a Klarity visit may fit · Learn about online anxiety treatment

FAQ

Is Imap available in the United States?

No commercial U.S. Imap or Redeptin product is on standard pharmacy shelves. Families usually need an FDA-available substitute, not an import.

Is fluspirilene the same as pimozide (Orap)?

They share the diphenylbutylpiperidine class (ATC N05AG). Pimozide is an oral tablet with a U.S. Tourette label and strict ECG rules. Fluspirilene is a weekly intramuscular depot used abroad for schizophrenia.

How often was Imap given?

Historic tables describe about 2-12 mg intramuscularly once a week. That is not a current U.S. order.

Does insurance cover fluspirilene?

Coverage varies by plan. A U.S. plan typically will not list a drug that U.S. pharmacies do not stock. Verify benefits before you book. Klarity cannot guarantee coverage.

Can I start this online?

No. Klarity does not prescribe fluspirilene. A visit can still review current symptoms and medicines that are actually available here.

Disclaimer

This article is education, not medical advice, diagnosis, or a promise of treatment or insurance payment. Medication decisions belong to you and a licensed clinician. If you may harm yourself or someone else, call 911 or 988.

Sources: DrugBank DB04842; Wikipedia: Fluspirilene; Cochrane CD001718; HHS telehealth policy updates.